Currently approved c checkpoint inhibitors for the treatment of melanoma include an anti-CTLA-4 antibody ipilimumab, an anti-PD-1 antibodies nivolumab and pembrolizumab, correspondingly, their related research has also proved to be one of the hot topics in our result (77–79). Here, CTLA4 is linked to melanoma.